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Abstract
Background: Although fungi have been implicated as initiating/deteriorating factors for allergic asthma, their
contributing components have not been fully elucidated. We previously isolated soluble β-glucan from Candida
albicans  (CSBG) (Ohno et al., 2007). In the present study, the effects of CSBG exposure on airway
immunopathology in the presence or absence of other immunogenic allergen was investigated in vivo, and their
cellular mechanisms were analyzed both in vivo and in vitro.
Methods: In vivo, ICR mice were divided into 4 experimental groups: vehicle, CSBG (25 μg/animal), ovalbumin
(OVA: 2 μg/animal), and CSBG + OVA were repeatedly administered intratracheally. The bronchoalveolar lavage
cellular profile, lung histology, levels of cytokines and chemokines in the lung homogenates, the expression pattern
of antigen-presenting cell (APC)-related molecules in the lung digests, and serum immunoglobulin values were
studied. In vitro, the impacts of CSBG (0–12.5 μg/ml) on the phenotype and function of immune cells such as
splenocytes and bone marrow-derived dendritic cells (BMDCs) were evaluated in terms of cell proliferation, the
surface expression of APC-related molecules, and OVA-mediated T-cell proliferating activity.
Results: In vivo, repeated pulmonary exposure to CSBG induced neutrophilic airway inflammation in the absence
of OVA, and markedly exacerbated OVA-related eosinophilic airway inflammation with mucus metaplasia in mice,
which was concomitant with the amplified lung expression of Th2 cytokines and IL-17A and chemokines related
to allergic response. Exposure to CSBG plus OVA increased the number of cells bearing MHC class II with or
without CD80 in the lung compared to that of others. In vitro, CSBG significantly augmented splenocyte
proliferation in the presence or absence of OVA. Further, CSBG increased the expression of APC-related
molecules such as CD80, CD86, and DEC205 on BMDCs and amplified OVA-mediated T-cell proliferation
through BMDCs.
Conclusion: CSBG potentiates allergic airway inflammation with maladaptive Th immunity, and this potentiation
was associated with the enhanced activation of APCs including DC.
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Background
Bronchial asthma has been recognized as a chronic type of
allergic airway inflammation with hyperresponsiveness to
foreign allergens. Almost all allerologists know that
allergy including asthma involves a significant genetic
component; however, to explain the rapid rise in the prev-
alence of asthma and allergic diseases over the past 40
years, we must consider environmental factors and trig-
gers [1]. Thus, understanding the nature of environmental
triggers is fundamental in attempts to prevent/reduce
allergic diseases, in particular, in the next generation. As
previously noted, among environmental triggers/factors,
exposure to common aeroallergens, especially perennial
inhalable allergens such as house dust mite, companion
animal allergens, cockroach allergen, and pollutants, is
associated with a significantly increased risk for asthma
[2,3]. Fungal spores are also important, since their growth
is a common problem in moisture- and water-damaged
buildings [3-5]. Given the evidence of the importance of
exposure to fungi including molds as an environmental
risk factor for asthma, some epidemiological data have
been reported on the link between airborne fungi and
asthmatic subjects [6,7], e. g. exposure to fungi in indoor
air is thought to induce allergic asthma in susceptible sub-
jects [8]. More importantly, fungi may increase allergic
reactions to other allergens as adjuvants [8]. However,
there is still a shortage of experimental evidence regarding
the correlation between fungi and allergic diseases. Fur-
thermore, it remains unknown which components of the
fungal organisms are responsible for the induction/adju-
vant effects on allergic asthma.
β-glucan of fungi reportedly possesses various biological
activities [9,10], being implicated in the development of
mycosis. However, the activities of the component have
not been appropriately elucidated, because it cannot be
solubilized easily in water and alkali solutions, resulting
in a difficulty to examine it experimentally [11]. We have
succeeded in the extraction of a soluble β-glucan from C.
albicans (CSBG), recognized to be a major opportunistic
pathogen in humans, and analyzed its biological effects
[12]. We previously reported its immunopharmacological
activities such as the production of proinflammatory
cytokines in vitro [13] and antitumor activity in vivo [14].
Also, we demonstrated that a single pulmonary exposure
to CSBG induces lung inflammation characterized by the
infiltration of inflammatory leukocytes including eosi-
nophils with an enhanced lung expression of proinflam-
matory cytokines and chemokines, with a possible link to
the activation of signal transducer and activator of tran-
scription (STAT)6 [15], implicating that CSBG can
induce/facilitate allergic airway inflammation, in which
STAT6 pathway plays an important role. Furthermore,
some previous studies have implied that gastrointestinal
tract colonization by Candida  enhances allergic airway
responses in vivo [16,17] and in humans [18].
The present study explored whether repetitive pulmonary
exposure to CSBG induces allergic type airway inflamma-
tion and/or potentiates other allergen (ovalbumin: OVA)-
induced allergic airway inflammation in mice. Further, we
examined the impact of CSBG on immune cells such as
splenocytes and bone marrow-derived dendritic cells
(BMDCs) in vitro to identify cellular mechanisms underly-
ing CSBG's facilitation on allergic inflammation.
Methods
Reagents
CSBG was purified using the NaClO-DMSO method from
the yeast form of C. albicans NBRC1385 cultured on C-
limitting medium, as previously described [13]. Briefly, C.
albicans was oxidized with NaClO solution, and the result-
ing insoluble part was collected and extensively washed
and dialyzed with distilled water. Finally, the insoluble
part (NaClO-oxidized candida: OX-CA) was dried by ace-
tone and ether. OX-CA was essentially composed of β-glu-
can and free from nitrogen based on elemental analysis.
CSBG was extracted from OX-CA by dimethyl sulfoxide
(DMSO: Sigma Chemical, St. Louis, MO) and precipitated
using acetone and ether. Thus, CSBG is a purified prepara-
tion of solubilized cell wall β-glucan of C. albicans. The
structure of CSBG was determined by elemental analysis,
β-1,3-glucanase digestion, MALDI-TOF-MASS analysis,
and NMR spectroscopy as β-1,3-glucan carrying β-1,6-β
segment [13]. The activity of OX-CA (parent material of
CSBG) was completely dependent on dectin-1, a β-glucan
receptor, by using alveolar macrophage from dectin-1
knockout mice, suggesting that CSBG is a ligand of dectin-
1 [19]. CSBG was dissolved in DMSO. The endotoxin
activity which was determined using the Limulus Amebo-
cyte Lysate assay (Seikagaku-kogyo, Tokyo, Japan), was
lower than the detection limit (0.001 EU/ml) in the vehi-
cle and CSBG.
Animals
Male ICR mice 6 wk of age (Japan Clea Co., Tokyo, Japan)
were used for the in vivo studies; mice 11–13 wk of age
were used for in vitro studies. Mice were housed in an ani-
mal facility maintained at 24 to 26°C with 55 to 75%
humidity and a 12-h light/dark cycle, and fed a commer-
cial diet (Japan Clea Co.) and given water ad libitum. The
studies adhered to the National Institutes of Health guide-
lines for the experimental use of animals. All animal stud-
ies were approved by the Institutional Review Board of the
National Institute for Environmental Studies.
In vivo studies
Study protocol
Mice were divided into four experimental groups. The
vehicle group received vehicle (phosphate-buffered
saline: PBS at pH 7.4 [Invitrogen Co., Carlsbad, CA, USA]
containing 2% DMSO) every 2 wk for 4 wk (total: 3
times). The OVA group received 2 μg of OVA (Grade IV:Respiratory Research 2009, 10:68 http://respiratory-research.com/content/10/1/68
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Sigma Chemical: endotoxin activity was lower than the
detection limit) dissolved in the same vehicle every 2 wk
for 4 wk (total: 3 times) to elicit allergic airway inflamma-
tion according to the previous study by our laboratory
[20]. The CSBG group received (12.5 or) 25 μg of CSBG
suspended in the same vehicle every 2 wk for 4 wk (total:
3 times). This protocol was confirmed to significantly
facilitate this type of allergic asthma when intratracheally
administered 3 times, since the effect of a 6-times CSBG
exposure on the pathology was not different from a 3-
times exposure. The CSBG + OVA group received the com-
bined treatment using the same protocol as the OVA and
CSBG groups, respectively. In each group, vehicle, CSBG,
OVA, or CSBG + OVA was dissolved in 0.1-ml aliquots,
and inoculated by the intratracheal route through a poly-
ethylene tube under anesthesia with 4% halothane
(Hoechst, Japan, Tokyo, Japan). Twenty-four h after the
last intratracheal administration, mice were sacrificed and
sera and the lungs were collected for bronchoalveolar lav-
age (BAL) cellularity, lung histology, lung cytokine pro-
file, and OVA-specific antibody assay. In other
experiments, 4 h after the last intratracheal administra-
tion, mice were sacrificed and the lungs were collected for
FACS analysis.
BAL and histological evaluation
BAL and cell counts were conducted as previously
described [20-22] (n = 8 in each group). After the BAL pro-
cedure, the lungs were removed, snap-frozen in liquid
nitrogen, and stored at -80°C for ELISA. Histological eval-
uation was conducted using hematoxylin and eosin
(H&E) staining (International Reagents Co., Kobe, Japan)
or periodic acid-Schiff (PAS) (n = 5 in each group), as pre-
viously described [21,22].
Morphometric analysis of numbers of polymorphonuclear leukocytes 
(PMNs), mononuclear cells (MONs), and mucus cells
On another occasion, sections were stained with Diff-
Quik to quantify the numbers of infiltrated PMNs and
MONs. The length of the basement membrane of airways
was measured by videomicrometer (Olympus Co., Tokyo,
Japan) in each sample slide. The numbers of PMNs and
MONs around the airways were counted with a microme-
ter under oil immersion. The results are expressed as the
number of inflammatory cells per millimeter of basement
membrane, as described previously [21] (n = 5 in each
group). To quantify mucus cells, sections were stained
with PAS. The number of mucus cells in the bronchial epi-
thelium was counted using a micrometer. The results are
expressed as the number of mucus cells per millimeter of
basement membrane, as described previously [21] (n = 5
in each group).
Quantification of cytokines in lung tissue homogenates
Frozen lungs were subsequently homogenized, as
described previously [21,22]. ELISAs for interleukin (IL)-
4 (Amersham, Buckinghamshire, UK), IL-5 (Endogen,
Cambridge, MA), IL-13 (R&D systems, Minneapolis,
MN), interferon (IFN)-γ (Endogen), IL-17A (BioLegend,
Inc., San Diego, CA), granulocyte/macrophage-colony-
stimulating factor (GM-CSF), eotaxin, macrophage
inflammatory protein (MIP)-1α, and keratinocyte-derived
chemoattractant (KC)(R&D systems) in the lung tissue
homogenates were conducted according to the manufac-
turer's instructions (n = 8 in each group).
Total IgE and OVA-specific Ig determination
Total IgE, OVA-specific IgG1, IgG2a, or IgE antibodies was
measured by ELISA using sera obtained from blood, as
previously described [20,21]. In brief, for total IgE, micro-
plate wells were coated with a rat anti-mouse IgE mono-
clonal antibody (Yamasa Syoyu Co., Chiba, Japan) and
diluted samples were introduced. After incubation, bioti-
nylated rat anti-mouse IgE (BD Biosciences Pharmingen,
San Diego, CA) was added to each well. Thereafter, the
wells were incubated with 4-methylumbelliferyl-β-galac-
toside (Sigma Chemical) as the enzyme substrate. The flu-
orescene intensity was read by a microplate fluorescene
reader (Fluoroskan Flow Laboratories, Costa Mesa, CA)(n
= 13 in each group). For OVA-specific IgG1 and IgG2a,
microplate wells (Dynatech, Chantilly, VA) were coated
with OVA. Diluted samples were added to the microplate
and the bound IgG1 was detected with biotinylated rabbit
anti-mouse IgG1 or IgG2a (Zymed Laboratories, San Fran-
cisco, CA). Color development was achieved using horse-
radish-peroxidase-conjugated streptavidin (Sigma
Chemical) followed by the addition of o-phenylenedi-
amine and H2O2. Optimal density readings of samples at
492 nm were obtained, and results were expressed in titers
calculated based on the titers of the standard serum (n =
13 in each group). OVA-specific IgE was measured using
an ELISA kit (Dainippon Sumitomo Pharmaceutical Co.,
Osaka, Japan) according to the manufacturer's instruc-
tions. Subtractive readins at 450 nm was converted to ng/
ml using values obtained from standard curves generated
with varying concentrations of anti-OVA antibodies (n =
13 in each group).
Preparation of lung cells and FACS analysis
Mice were anesthetized with sodium pentobarbital (Dain-
ippon Sumitomo Pharmaceutical Co.) given intraperito-
neally (50 mg/kg), and exsanguinated from the cut
abdominal aorta and vein. The lung cells were prepared as
previously described [20]. Briefly, the lung vessel was per-
fused with 2 ml of chilled PBS containing 0.2% bovine
serum albumin (BSA; Sigma Chemical) and 10 U/ml
heparin (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) introduced into the right ventricle. The lung tissue
was sliced and digested for 90 min at 37°C in 2 ml of PBS
containing 0.2% BSA, 0.25 mg/ml collagenase A (Boe-
hringer Mannheim, Mannheim, Germany), and 50 U/ml
DNAase I (Sigma Chemical). After teasing the digested tis-Respiratory Research 2009, 10:68 http://respiratory-research.com/content/10/1/68
Page 4 of 12
(page number not for citation purposes)
sue and filtration through cotton wool, single cell suspen-
sions were collected. The numbers of viable cells were
determined by the trypan blue exclusion method.
For FACS analysis, the following monoclonal antibodies
were used: MHC class II molecules: I-A/I-E (2G9, FITC-
conjugated, BD Biosciences Pharmingen); co-stimulatory
molecules: CD80 (16-10A1, PE-conjugated, BD Bio-
sciences Pharmingen), CD86 (GL1, PE-conjugated, BD
Biosciences Pharmingen), DC markers: CD11c (HL3, PE-
conjugated, BD Biosciences Pharmingen), DEC-205
(NLDC-145, PE-conjugated, Cedarlane Labs, Ontario,
Canada), a macrophage marker: F4/80 (CI:A3-1, PE-con-
jugated, Serotec, Oxford, UK); a B-cell differentiation anti-
gen: CD19 (6D5, PE-conjugated, Southern
Biotechnology, Birmingham, AL). Immunostaining was
conducted as previously described [20,23,24], and flow
cytometry was performed using a FACSCalibur (Becton,
Dickinson and Company, NJ). Fluorescence data are
expressed as the percentage of positive cells. Finally, the
number of positive cells was calculated and expressed for
each group (n = 8 in each group).
In vitro studies
Preparation of bone marrow cells and splenocytes
Mice were anesthetized with sodium pentobarbital and
exsanguinated from the cut abdominal aorta and vein.
After removing the surrounding muscle tissue by rubbing
with kleenex® tissues, the bones were left in 70% ethanol
for 3 min and washed with Dulbecco's calcium and PBS.
Both ends of the bones were cut and then the marrow was
flushed with PBS using a syringe with a 25G needle. The
marrow suspension was passed through nylon mesh to
remove small pieces of bone and debris and red blood
cells were lysed with ammonium chloride. The spleen was
pushed through a sterile stainless wire mesh (200 mesh)
and red blood cells were also lysed with ammonium chlo-
ride. The cells were centrifuged at 400 × g for 5 min at
20°C. After washing twice with PBS, the cells were resus-
pended in the culture medium R10, which was GIBCO
RPMI 1640 medium (Invitrogen Co.) supplemented with
10% heat-inactivated fetal bovine serum (FBS; MP Bio-
medicals Inc., Eschwege, Germany), 100 U/ml penicillin,
100 μg/ml streptomycin (Sigma Chemical), and 50 μM 2-
mercaptoethanol (Invitrogen Co.). The numbers of viable
cells were determined by the trypan blue (Invitrogen Co.)
exclusion method.
Differentiation of BMDCs
BMDCs were differentiated using a modified protocol of
Lutz et al [25]. In brief, bone marrow cells (4 × 105/ml)
were cultured in R10 medium containing 20 ng/ml
recombinant mouse GM-CSF (Sigma Chemical) at 37°C
in a 5% CO2/95% air atmosphere. On day 3, another
same volume of medium was added to the culture. At day
6 of culture, half of the culture medium was poured into
fresh R10 medium containing 20 ng/ml GM-CSF. At day
8 of culture, non-adherent and loosely adherent cells were
collected by gentle pipetting, and centrifuged at 400 × g
for 5 min at 20°C. These cells (immature BMDC) were
resuspended in the medium. The numbers of viable cells
were determined by the trypan blue exclusion method.
Exposure to CSBG in vitro
CSBG was dissolved in PBS. BMDCs were differentiated
by culture with GM-CSF as described above. Differenti-
ated BMDCs (1 × 106/ml) on day 8 of culture with GM-
CSF (20 ng/ml) were exposed to CSBG (1.25–12.5 μg/ml)
or 0.1% DMSO (control) in the presence of GM-CSF (10
ng/ml) for 24 h. Thereafter, the phenotypes and function
of BMDCs were evaluated in terms of the expression pat-
tern of surface markers and antigen-presenting activity.
On the other hand, splenocytes (1 × 106/ml) were
exposed to CSBG (1.56–12.5 μg/ml) or 0.1% DMSO
(control) in the presence or absence of 100 μg/ml OVA for
72 h, and then the cell.
FACS analysis
For FACS analysis, the following monoclonal antibodies
were used: I-A/I-E, CD80, CD86, CD11c, and DEC-205.
FACS analysis was performed using the same protocol as
in the in vivo study. This experiment was repeated four
times using two to three animals in each group.
Evaluation of antigen-presenting activity of BMDCs
CSBG-exposed BMDCs were treated with 50 μg/ml mito-
mycin C (Kyowa Hakko Kogyo, Tokyo, Japan) for 20 min
in a water bath at 37°C. Responder T cells were derived
from a pool of splenocytes from OVA-sensitized ICR mice
(three mice/each experiment). Briefly, mice were immu-
nized with 40 μg OVA and 1 mg Al(OH)3 in 0.1 ml of
saline given intraperitoneally, and splenocytes were har-
vested on day 14. T cells were isolated from the spleno-
cytes using a nylon fiber column (Wako Pure Chemical
Industries). Thereafter, OVA-sensitized T cells (2 × 105)
were co-cultured with BMDCs (5 × 103) in the presence of
20 μg of OVA in 200 μl of R10 medium in 96-well flat-
bottom plates. The co-culture of BMDCs and T cells was
performed in triplicate at 37°C in a 5% CO2/95% air
atmosphere. After 91 h, cell proliferation and cytokine
production from T cells were measured. The same experi-
ment was repeated three times using three animals per
group.
Measurement of cell proliferation
Cell proliferation was measured with a Cell-Proliferation-
ELISA Kit (Roche Molecular Biochemicals, Mannheim,
Germany) according to the manufacturer's instructions.
This technique is based on the incorporation of the pyri-
midine analogue 5-bromo-2'-deoxyuridine (BrdU)
instead of thymidine into the DNA of proliferating cells.
BrdU incorporated into DNA is measured by a sandwich-Respiratory Research 2009, 10:68 http://respiratory-research.com/content/10/1/68
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type enzyme immunoassay using monoclonal anti-BrdU
antibodies. Cell proliferation was measured by adding
BrdU to each well 20 h before measurement. Absorbance
of the samples was measured in an ELISA plate reader at a
wavelength of 450 nm.
Statistical analysis
Data are reported as the mean ± SE using Statview version
4.0 (Abacus Concepts, Inc., Berkeley, CA). To examine
each (CSBG and OVA) factor's effect and interaction in the
combination, two-way ANOVA was performed for in vivo
results. Regarding in vitro studies, one-way ANOVA was
applied. Bonferroni corrections were used for post hoc
tests to examine the difference between the two groups.
Significance was assigned to P-values smaller than 0.05.
Results
Effects of pulmonary exposure to CSBG on lung 
inflammation in the presence or absence of OVA
We investigated the cellular profile of BAL fluid and exhib-
ited representative data (25 μg of CSBG used: Fig. 1). The
number of total cells was significantly greater in the CSBG
or CSBG + OVA group than in the vehicle group (P <
0.01). The number was significantly greater in the CSBG +
OVA group than in the OVA group (P < 0.01). Exposure to
CSBG + OVA increased the number of eosinophils as com-
pared with vehicle exposure (P < 0.01). The number was
significantly greater in the CSBG + OVA group than in the
CSBG or OVA group (P < 0.01), and synergistic interac-
tion between the two stimulators was noted (P = 0.02).
The number of lymphocytes was significantly greater in
the CSBG + OVA group than in the vehicle group (P <
0.01). The number was greater in the CSBG + OVA group
than in the OVA group (P < 0.05). The number of neu-
trophils was significantly greater in the CSBG (P < 0.01),
OVA (P < 0.05), or CSBG + OVA (P < 0.01) group than in
the vehicle group. The number was significantly higher in
the CSBG + OVA group than in the OVA group (P < 0.01).
The number of macrophages was greater in the CSBG +
OVA group than in the vehicle group (P < 0.01). The
number was further significantly greater in the CSBG +
OVA group than in the OVA group (P < 0.05). On the
other hand, in experiments using 12.5 μg of CSBG, the
data are similar as that using 25 μg, although the signifi-
cance did not show profoundly (data not shown).
Effects of CSBG on histological changes in the lung in the 
presence or absence of OVA
We evaluated lung specimens stained with H&E 24 h after
the final intratracheal instillation (Fig. 2). No pathologi-
cal change was noted in lungs obtained from the vehicle
group. The infiltration of neutrophils was moderate in the
lungs from the CSBG and modest in those from the OVA
group. On the other hand, the infiltration of eosinophils
was moderate in lungs from the OVA group. Combined
treatment with CSBG + OVA appeared to worsen PMN
and MON sequestration into the lung parenchyma, as
compared with OVA treatment alone.
To quantify the infiltration of inflammatory leukocytes
around the airways, we expressed the number of these
cells per length of basement membrane of the airways.
The number of PMNs was greater in the CSBG (P < 0.05),
OVA (P < 0.05), or CSBG + OVA (P < 0.01) group than in
the vehicle group. The number was also significantly
greater in the CSBG + OVA group than in the CSBG group
(P < 0.05). The number of MONs was larger in the CSBG
+ OVA group than in the vehicle group (P < 0.05).
CSBG exacerbates OVA-induced mucus metaplasia
To evaluate airway epithelial injury and mucus hyperse-
cretion, lung sections were stained with PAS (Fig. 3).
CSBG or OVA alone induced modest mucus cell hyperpla-
sia in the airway compared with the vehicle. However, the
phenomenon markedly progressed in the CSBG + OVA
group compared to the other groups. Semi-quantitative
analyses also showed that CSBG or OVA alone modestly
increased the number of mucus cells as compared with the
vehicle. On the other hand, the number was significantly
greater in the CSBG + OVA group than in the vehicle,
CSBG, or OVA group (P < 0.01), and synergistic interac-
tion between the two stimulators was noted (P = 0.02).
Cellularity in bronchoalveolar lavage (BAL) fluid after intrat- racheal challenge Figure 1
Cellularity in bronchoalveolar lavage (BAL) fluid 
after intratracheal challenge. Four groups of ICR mice 
were intratracheally administered vehicle, soluble β-glucan 
from Candida albicans (CSBG), ovalbumin (OVA), or CSBG + 
OVA for 4 wk. Bronchoalveolar lavage (BAL) was conducted 
24 h after the last intratracheal instillation. Total cell counts 
were determined on fresh BAL fluid, and differential cell 
counts were assessed with Diff-Quik-staining. The results are 
presented as the mean ± SE (n = 8 in each group). *P < 0.05 
and **P < 0.01 vs. vehicle; # P < 0.05 and ## P < 0.01 vs. OVA; 
$ P < 0.01 vs. CSBG.Respiratory Research 2009, 10:68 http://respiratory-research.com/content/10/1/68
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Effects of CSBG on the lung expression of cytokines and 
chemokines in the presence or absence of OVA
We quantified protein levels of cytokines such as IL-4, IL-
5, IL-13, IFN-γ, IL-17A, and GM-CSF,, and chemokines
such as eotaxin, MIP-1α, and KC related to allergic inflam-
mation in the lung tissue homogenates (Fig. 4). Pulmo-
nary exposure to CSBG elevated the levels of MIP-1α and
KC compared to vehicle exposure (P < 0.05). OVA ele-
vated the levels of IL-5 and IL-13 as compared to vehicle
exposure (P < 0.05). On the other hand, CSBG plus OVA
markedly increased the levels of all cytokines and chem-
okines compared to the vehicle (P < 0.05 for IL-4, IL-17A,
and GM-SCF; P < 0.01 for IL-5, IL-13, eotaxin, MIP-1α,
and KC), CSBG (P < 0.05 for IL-4; P < 0.01 for IL-5, IL-13,
eotaxin, MIP-1α, and KC), or OVA (P < 0.05 for IL-4, IL-
13, IL-17A, and GM-CSF; P < 0.01 for IL-5, eotaxin, MIP-
1α, and KC). Furthermore, two-way ANOVA revealed syn-
ergistic interactions between CSBG and OVA on IL-4, IL-5,
IL-13, IL-17A, eotaxin, MIP-1α, and KC (P < 0.05). IFN-γ
level was not different between the experimental groups
(data not shown).
Effects of CSBG on the production of Igs in the presence or 
absence of OVA
We measured total IgE and OVA-specific IgG1, IgE, and
IgG2a levels (Fig. 5). The total IgE level was greater in the
CSBG + OVA group than in the other groups (N. S.). The
OVA-specific IgG1 titer was higher in the OVA (P < 0.05)
or CSBG + OVA (P < 0.01) group than in the vehicle
group. The titer was further greater in the CSBG + OVA
group than in the CSBG group (P < 0.05). OVA-specific
IgE concentration was greater in the CSBG + OVA group
than in the vehicle group (P < 0.05). The value was also
greater in the CSBG + OVA group than in the CSBG group
Histological findings of hematoxylin and eosin (H&E)-stained  lungs Figure 2
Histological findings of hematoxylin and eosin (H&E)-
stained lungs. The 4 groups of mice were intratracheally 
inoculated with vehicle, CSBG, OVA, or CSBG + OVA for 4 
wk. Lungs were obtained 24 h after the final intratracheal 
administration, and representative photographs of H&E-
stained lung tissues are shown. Original magnification ×100. 
Polymorphonuclear leukocyte (PMN) and mononuclear cell 
(MON) infiltration is expressed as the average number of 
PMNs and MONs per millimeter of basement membrane. 
Values represent the mean ± SE (n = 5 in each group). * P < 
0.01 vs. vehicle; $ P < 0.05 vs. CSBG.
Histological findings of the periodic acid Schiff (PAS)-stained  lungs Figure 3
Histological findings of the periodic acid Schiff (PAS)-
stained lungs. The 4 groups of mice were intratracheally 
inoculated with vehicle, CSBG, OVA, or CSBG + OVA for 4 
wk. Lungs were obtained 24 h after the final intratracheal 
administration and representative photographs of PAS-
stained lung tissues are shown. Original magnification × 200. 
Mucus cell hyperplasia in the bronchial epithelium is 
expressed as the average number of PAS-positive cells per 
millimeter of basement membrane. Values represent the 
mean ± SE (n = 5 in each group). * P < 0.01 vs. vehicle; # P < 
0.01 vs. OVA; $ P < 0.01 vs. CSBG.Respiratory Research 2009, 10:68 http://respiratory-research.com/content/10/1/68
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(P < 0.05). The OVA-specific IgG2a titer was higher only in
the CSBG + OVA group than in other groups (P < 0.05).
Effects of in vivo exposure to CSBG on the expression of 
MHC class II with or without costimulatory molecules and 
APC-related markers in lung cells in the presence or 
absence of OVA
The number of MHC class II+ cells was greater in the CSBG
+ OVA group than in the other groups (P < 0.05)(Fig. 6).
Also, a two-way ANOVA revealed an interaction between
CSBG and OVA on the number (P = 0.04). The number of
CD80+ or CD86+ cells was greater in the CSBG + OVA
group than in the vehicle group (P < 0.05 for CD80+, P <
0.01 for CD86+). Furthermore, the number of MHC class
II+ CD80+ or MHC class II+ CD86+ cells was also greater in
the CSBG + OVA group than in the vehicle group (P < 0.05
for MHC class II+ CD86+, P < 0.01 for MHC class II+
CD80+). The number of MHC class II+ CD80+ was further
greater in the CSBG + OVA group than in the OVA group
(P < 0.05). In addition, a two-way ANOVA revealed an
interaction between CSBG and OVA on the number of
MHC class II+ CD80+ (P = 0.045). The number of MHC
class II+ CD11c+ cells was higher in the CSBG (P < 0.05) or
the CSBG + OVA (P < 0.01) group than in the vehicle
group.
The number of MHC class II+ DEC205+ cells was greater in
the CSBG + OVA group than in the vehicle group (P <
0.05). On the other hand, the number of F4/80+ or CD19+
cells with or without MHC class II+ was not significantly
different among the experimental groups.
Effects of CSBG on splenocyte proliferation in vitro
The proliferation of splenocytes was examined after expo-
sure to CSBG or DMSO (control) in the presence or
absence of OVA for 72 h (Fig. 7). Exposure to CSBG
increased splenocyte proliferation in the absence of OVA
in a dose-dependent manner showing an overall trend,
with significance at a dose of 12.5 μg/ml (P < 0.05: Fig.
7A). Also, CSBG increased it in the presence of OVA in a
dose-independent manner (maximal activity at 1.56 μg/
ml: P < 0.05: Fig. 7B).
Action of CSBG on the expression of surface molecules on 
BMDCs in vitro
Immature BMDCs were exposed to CSBG for 24 h. The
surface expression of MHC class II, CD80, CD86, CD11c,
and DEC205 (Fig. 8) on cells was analyzed to estimate the
maturation/activation of BMDCs. The percentage of
CD80+, CD11c+, DEC205+, MHC class II+CD80+, MHC
class II+ CD11c+, or MHC class II+ DEC205+ cells was
Protein levels of cytokines and chemokines in the lung  homogenates Figure 4
Protein levels of cytokines and chemokines in the 
lung homogenates. The 4 groups of mice were intratra-
cheally inoculated with vehicle, CSBG, OVA, or CSBG + 
OVA for 4 wk. Lungs were removed and frozen 24 h after 
the last intratracheal administration. Protein levels of inter-
leukin (IL)-4, IL-5, IL-13, IL-17A, granulocyte/macrophage-
colony-stimulating factor (GM-CSF), eotaxin, macrophage 
inflammatory protein (MIP)-1α (C), and keratinocyte-derived 
chemoattractant (KC) in the lung homogenate supernatants 
were analyzed using ELISA. The results are presented as the 
mean ± SE (n = 8 in each group). * P < 0.05 and ** P < 0.01 
vs. vehicle; # P < 0.05 and ## P < 0.01 vs. OVA; $ P < 0.05 and 
$$ P < 0.01 vs. CSBG.
Values of total IgE and OVA-specific IgG1, IgG2a, and IgE Figure 5
Values of total IgE and OVA-specific IgG1, IgG2a, and 
IgE. The 4 groups of mice were intratracheally administered 
vehicle, CSBG, OVA, or a combination of CSBG + OVA for 
4 wk. Serum samples were retrieved 24 h after the last 
intratracheal instillation. Total IgE and OVA-specific IgG1, 
IgG2a, and IgE were analyzed using ELISA. The results are 
expressed as the mean ± SE (n = 13 in each group). * P < 
0.05 and ** P < 0.01 vs. vehicle; # P < 0.01 vs. OVA; $ P < 0.01 
vs. CSBG.Respiratory Research 2009, 10:68 http://respiratory-research.com/content/10/1/68
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increased by the addition of CSBG in a dose-dependent
fashion with overall trend. Of note, the increase was pro-
foundly in the ratio of double highly positive cells (MHC
class IIhighCD80high, MHC class IIhighCD86high, and MHC
class IIhighDEC205high) with significance at its high dose
(12.5 μg/ml)(P < 0.05) as compared to control.
Effect of CSBG on the OVA-specific syngeneic T-cell-
stimulating capacity of BMDCs in vitro
BMDC function was assessed via their capacity to stimu-
late antigen-specific syngeneic T-cell proliferation (Fig. 9).
The proliferation of T cells (responder cells) was increased
by the addition of BMDCs (stimulator cells). The reaction
was significantly increased when BMDCs were exposed to
more than 1.25 μg/ml of CSBG. Furthermore, Th cytokine
(IL-4 and IFN-γ) levels in culture supernatants were meas-
ured by ELISA. Although the protein levels were increased
by CSBG exposure dose-independently, the difference did
not reach statistical significance (data not shown).
Discussion
The present study has demonstrated that repetitive pul-
monary exposure to CSBG potentiates OVA-related eosi-
nophilic airway inflammation with mucus metaplasia,
which is concomitant with the increased local expression
of proinflammatory cytokines including IL-4, IL-5, IL-13,
IL-17A, eotaxin, MIP-1α, and KC. Also, exposure to CSBG
plus allergen increases the numbers of MHC class II+ cells
and those expressing MHC class II and CD80 (a co-stimu-
latory molecule) in the lung as compared to that of others
in vivo. Finally, CSBG increases splenocyte proliferation
and partially promotes the phenotypic and functional
activation of BMDCs in vitro.
Correlation between fungi and allergic responses has been
implicated. Airborne fungi and their products may con-
tribute to the development and exacerbation of allergic
airway diseases [26,27]. Increased spore counts and fun-
gal allergen levels correlate with allergic symptoms [28-
30]. Consistent with these epidemiological reports, fungal
products including proteins reportedly induce immuno-
logic and proinflammatory reactions and consequent
Th2-related responses and the destruction of mucosal bar-
rier functions [31-33]. β-glucan from both outdoor
(Cladosporium herbarum) and indoor (Penicillium chrysoge-
num) fungi and from baker's yeast exhibit adjuvant prop-
erties for Th2 response related to OVA in vivo [8]. Further,
peripheral blood mononuclear cells (PBMCs) from
The number of cells expressing MHC class II, co-stimulatory  molecules, and leukocyte markers in the lung Figure 6
The number of cells expressing MHC class II, co-
stimulatory molecules, and leukocyte markers in the 
lung. The 4 groups of mice were intratracheally adminis-
tered vehicle, CSBG, OVA, or a combination of CSBG + 
OVA for 4 wk. Lung cells were prepared 4 h after the last 
intratracheal instillation. The expression of cell surface mole-
cules was analyzed by flow cytometry. The numbers of each 
cell type in the lung are shown. Values are presented as the 
mean ± SE (n = 8 in each group). * P < 0.05 and ** P < 0.01 
vs. vehicle; # P < 0.05 vs. OVA; $ P < 0.05 vs. CSBG.
Splenocyte proliferation Figure 7
Splenocyte proliferation. Splenocytes (1 × 106/ml) from 
naïve ICR mice were exposed to CSBG (1.56–12.5 μg/ml) or 
0.1% dimethyl sulfoxide (control) in the absence (A) or pres-
ence (B) of OVA (100 μg/ml) in 200 μl of R10 medium for 72 
h. Cell proliferation of splenocytes was evaluated by ELISA. 
Data represent the mean ± SE of three animals from one 
experiment representative of three experiments. * P < 0.05 
vs. control.Respiratory Research 2009, 10:68 http://respiratory-research.com/content/10/1/68
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asthma patients produced significantly higher IL-5 pro-
tein levels on stimulation with C. albicans than those from
non-allergic patients in vitro [34], implicating a role in the
exacerbation of asthma. However, scientific evidence
regarding the correlation between pathogenic fungi
including  C. albicans and allergic inflammation is not
enough.
Furthermore, investigation of the immunoregulatory
effects of cell wall components from fungi has been inad-
equate. Zymosan, a cell wall preparation mixed with β-
glucan and mannan residues from the fungus Saccharomy-
ces cerevisiae, is known to induce the production of proin-
flammatory cytokines and chemokines [35,36], and to
activate the complement system via an alternative path-
way [37,38]. Furthermore, zymosan can induce multiple
types of immunopathological diseases, resembling
human diseases, e.g., peritonitis [39] and arthritis [40], in
vivo. It has been indicated, on the other hand, that β-glu-
can itself serves various biological activities such as trig-
gering the activation of complement and the production
of inflammatory mediators including leukotrienes and
tumor necrosis factor-α [9,10,41]. However, it has not
been fully addressed how β-glucan derived from clinically
important pathogenic fungi modulates the immune
response, particularly in vivo. Given the background,
CSBG, isolated and solublized from C. albicans, may pro-
vide a hint for the impacts of nosocomial fungal infection
on the induction/aggravation of allergic airway inflamma-
tion, particularly in the context of its responsible constit-
uents.
In the present study, initially, we showed that repetitive
intratracheal exposure to CSBG did not induce allergic air-
way response in terms of lung eosinophilia, the Th2
response, or mucous hyperplasia, suggesting that the com-
ponent alone does not have potent Th2-related immuno-
genicity. Possible explanations for this unexpected
phenomenon may include the in vivo experimental proto-
col such as exposure means, dose, and/or duration, and
absence of adjuvant. In support of this, exposure to CSBG
alone induced a moderate activation of BMDCs and lym-
phocytes directly (through immunological synapse)/indi-
rectly in vitro. Moreover, we have previously found that a
single intratracheal administration of CSBG can induce
mucus hyperplasia, one of the consequences of the Th2
(IL-13)-dominant response and the enhanced phosphor-
ylation of STAT6, one of the pivotal transcriptional factors
in the Th2 milieu [42]. Thus, other protocols should be
examined in future in order to clarify the effects of suba-
cute/chronic exposure to CSBG on the induction of Th2
immunity with pathophysiology. On the other hand,
CSBG alone induced airway neutrophilia, whose mecha-
Surface expression of molecules related to antigen-presenta- tion on bone marrow-derived dendritic cells (BMDCs) Figure 8
Surface expression of molecules related to antigen-
presentation on bone marrow-derived dendritic cells 
(BMDCs). Immature BMDCs from ICR mice were exposed 
to CSBG as described in Materials and Methods. After expo-
sure, the expression of molecules related to antigen-presen-
tation was analyzed by flow cytometry. The percentages of 
each cell type in the BMDC population are shown. Data rep-
resent the mean ± SE of three animals from one experiment, 
representative of three experiments. * P < 0.05 vs. corre-
sponding control.
OVA-specific syngeneic T-cell-stimulating capacity of BMDCs Figure 9
OVA-specific syngeneic T-cell-stimulating capacity of 
BMDCs. Immature BMDCs from ICR mice were exposed to 
CSBG in the same manner as shown in Figure 8. Splenic T 
cells (2 × 105) from OVA-sensitized ICR mice were co-cul-
tured with BMDCs (5 × 103 for 1.25%) from mice in the 
presence of OVA (20 μg) in 200 μl of R10 medium for 4 d. 
Thereafter, T-cell proliferation was evaluated. Data repre-
sent the mean ± SE of three animals from one experiment, 
representative of three experiments. *P < 0.05 and **P < 
0.01 vs. control.Respiratory Research 2009, 10:68 http://respiratory-research.com/content/10/1/68
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nisms remain unidentified. We and others have shown
that Candida or CSBG can activate innate immunity to
produce KC (IL-8), a potent neutrophilic chemoattractant
[13,15,43]. Furthermore, CSBG has been shown to acti-
vate complement systems, including anaphylatoxin (C3a,
C5a) release [44]. Accordingly, these mechanisms could
be candidates. Alternate, the effects might be caused by
other unknown factors co-extracted from C. Albicans other
than endotoxin.
In turn, we showed that CSBG synergistically enhanced
allergic airway inflammation induced by OVA. The CSBG
plus OVA group exhibited significant augmentation of
eosinophilic lung inflammation with concomitant ampli-
fication of the lung expression of Th2 cytokines and
chemokines and related Ig productions in the circulation
compared to the OVA group. In addition, phosphoryla-
tion of STAT6 in the lung was more potently found in the
CSBG + OVA than in the other groups (evidenced by
Western blot analysis: data not shown). Thus, it is likely
that Candida-derived β-glucan can synergistically drive a
Th2-skewed pathophysiology related to another allergen
as a promoter, even if the dose is low enough to barely
induce eosinophilic inflammation in the absence of other
immunogenic allergen. However, why and how the mac-
romolecule glucose polymers displayed adjuvant effects
on the allergic condition when co-administered with rela-
tively low molecular weight OVA must be resolved in the
future.
The cellular target of CSBG in the exacerbation on allergic
airway inflammation induced by OVA is currently
unknown. Our first in vitro experiment implied that CSBG
can induce immune cell (splenocyte) activation in the
presence or absence of OVA. However, its detailed cellular
contribution is not known, since splenocytes contain
many immune cell populations such as macrophages/
monocytes, dendritic cells, and lymphocytes. Antigen-pre-
senting cells (APCs) are known to be important for both
innate and adaptive immunity. APCs including DCs, mac-
rophages, and B cells play essential roles in the pathogen-
esis of asthma [45-47]. In particular, DCs are recognized
as professional APCs, exhibiting a potent antigen-present-
ing capacity for T cells [48]. β-glucan of Candida report-
edly promotes the maturation of human monocyte-
generated DCs [49]. Therefore, we evaluated the effects of
CSBG on the phenotype and function of DCs in vitro. As a
result, although CSBG did not significantly enhance the
total expression of surface markers (DEC205, CD80, and
CD86) as an activation marker and accessory molecules
on BMDCs, the rate of highly expressed molecules was sig-
nificantly greater in the higher concentration of CSBG
than the control. On the other hand, CSBG exposure sig-
nificantly amplified OVA-specific syngeneic T cell reactiv-
ity against BMDC. Further, the numbers of cells expressing
MHC class II or MHC class II and CD80 in the lung were
significantly greater in the CSBG + OVA group than in the
other groups in vivo. Accordingly, the in vitro and in vivo
data may lead to the scenario that CSBG can synergisti-
cally increase the number of APCs recruited into the lung
in asthmatic mice, and, in turn, can amplify the functional
activation of APCs including DCs, which confer synergism
for the enhancement of asthma pathophysiology. This
notion is also supported by the observation that the lung
expression of GM-CSF was greater in the CSBG + OVA
group than in the other groups, since GM-CSF is a critical
cytokine for DC maturation/activation as applied in the
present in vitro study.
Whether CSBG preferentially enhances the Th2 response
remains obscure. In the present study, CSBG plus OVA
amplified the production of OVA-specific IgG2a as com-
pared to OVA alone in vivo and CSBG activated DC to pro-
duce/release higher levels of OVA-stimulated IFN-γ from T
cells than control, implicating its adjuvant activity for Th1
immunity as well as Th2 immunity in vivo and partially in
vitro. Furthermore, the lung level of IL-17A was signifi-
cantly greater in the CSBG + OVA group than in the CSBG
or OVA group. The Candida cell wall fraction reportedly
exacerbates collagen-induced arthritis, which is concomi-
tant with the elevation of IFN-γ and bovine type II colla-
gen-specific IgG2a [50]. On the other hand, C. albicans
extract induces IL-5 production from PBMCs in asthmatic
patients in vitro [51]. In addition, Th17 cells were recently
implicated in host immunity against Candida infection
[52] as well as allergic inflammation [53]. Thus, it may be
proposed that CSBG can induce both Th1- and Th2-, and
even Th17-mediated immunopathology, whose domi-
nance may depend on the study designs (in vivo, in vitro),
tissues (lung, joint)/cells (isolated/generated from splen-
ocytes, PBMCs), and/or the driving mode (Th1/Th2/Th17
conditions). Otherwise, from our present results, it is
likely that CSBG disrupts Th immunity, especially under
pathological Th conditions, in vivo.
Conclusion
In summary, repetitive pulmonary exposure to CSBG
facilitated allergic lung inflammation, at least partly, via
the enhanced expression of Th cytokines. As for possible
cellular mechanisms, these CSBG's effects were correlated
with the phenotypic and functional activation of APCs
including DCs, and partly with the migration/infiltration
of these cell populations in the inflamed tissues. These
results provide evidence for pathogenesis of asthma devel-
opment and/or exacerbation due to (biological and resi-
dence) environmental factors.
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